Introduction
Transplantation is the therapy of choice for patients with end-stage organ failure, but long-term allograft survival and function remain suboptimal, particularly for recipients of deceased donor organs whose graft half-lives are significantly shorter than those of living donor transplants (1) .
Many studies have shown that ischemia followed by reperfusion of native or transplanted organs initiates reactive oxygen radical-dependent inflammatory responses that mediate organ injury and dysfunction (2) (3) (4) (5) (6) (7) . While severe I/R injury can result in organ failure, transient I/R injury commonly resolves over days to weeks. Emerging evidence indicates that the poorer long-term survival of deceased donor organs is in part attributable to persistent inflammation initiated by early posttransplantation I/R injury (8) (9) (10) (11) . How these early events are linked to subsequent T cell-mediated graft injury is not well understood.
In work published since 2014, the Fairchild laboratory has advanced this field through studying a murine model of I/R-initiated cardiac allograft rejection in which donor hearts are exposed to 8 h of cold ischemic storage (CIS) before transplantation (12) . These studies showed that 8 h of allograft CIS triggers cytotoxic T-lymphocyte associated protein 4 (CTLA4)Ig-resistant, T cell-dependent rejection. Associated mechanistic studies indicated that the I/R injury augments allograft immunogenicity, facilitates activation and amplification of preexisting (endogenous) donor-reactive pathogenic memory T cells, and enhances rapid donor-reactive memory T cell infiltration into the allograft. Together, these events drive immunemediated graft rejection/failure despite dosing of CTLA4Ig that prevents rejection of allografts derived from the same donor strain but exposed to only 30 min of CIS (12) .
Several research groups, using rodent and large animal models, have shown a crucial role for the complement system as a proximal mediator of heart or kidney I/R injury (7, (13) (14) (15) (16) . Evidence indicates I/R injury induces neoantigen upregulation on the injured organ that binds collectins, natural autoreactive IgM, and/or mannose binding lectin (MBL) to initiate complement activation (4, 14, (16) (17) (18) . Downstream effectors include the anaphylatoxins C3a and C5a,which ligate their respective receptors, C3a receptor (C3aR) and C5a receptor (C5aR), on both graft cells and bone marrow-derived immune cells to mediate inflammation (19) (20) (21) (22) . While emerging evidence from murine models and humans indicate that heart transplantation initiates antibody-dependent complement activation (18) , whether and how complement participates in posttransplantation, I/R-initiated cardiac allograft rejection has not been studied.
Here, we used genetic knockouts and pharmacological inhibitors to test the impact of complement in the pathogenesis of prolonged I/R-induced, costimulatory blockade-resistant cardiac allograft rejection in mice. In addition to providing new mechanistic insight, the data provide preclinical evidence that peritransplantation complement inhibition should be explored as an approach to prevent CTLA4Ig-resistant rejection in human recipients of deceased donor allografts. (24) were rederived as an in-house colony. All animals were maintained in specific pathogen-free conditions, and studies were approved by the IACUC at Icahn School of Medicine at Mount Sinai. All transplant studies were performed with wildtype (WT) and knockout (KO) animals cohoused at Mount Sinai to control for interinstitutional differences in gut microbiomes.
Materials and Methods

Animals and procedures
Heterotopic heart transplantations were performed in our laboratories as previously described (12, 25) . Allografts were subjected to standard (30 min) 
Polymerase chain reaction
RNA isolation, cDNA synthesis, RT, and real-time RT-polymerase chain reaction (PCR) were performed as described previously (26) . Briefly, RNA was isolated from allograft cardiac tissue by using TRIzol (Thermo Fisher Scientific, Waltham, MA). cDNA was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) as per the manufacturer instructions. Quantitative PCR was performed with TaqMan primers (Thermo Fisher Scientific) and run on the CFX96 Real-Time System (Bio-Rad Laboratories, Hercules, CA). PCR products were normalized to the 18S control gene and expressed as fold increase over the mean value of WT?WT cardiac isograft samples using the DDCt method.
Cytokine enzyme-linked immunosorbent spot assays
Enzyme-linked immunosorbent spot (ELISPOT) assays were performed at 21 days posttransplantation as previously described (25) . Plates were developed and spots were analyzed on the ImmunoSpot Series 3 analyzer (CTL, Shaker Heights, OH).
Flow cytometry
Surface and intracellular staining was performed as previously described (27) . Antibodies were purchased from eBioscience, San Diego (Viability, CD45.1, CD45.2), Biolegend, San Diego (CD4, CD8), and anti-1B2 to identify 2C (G. Hadley, OSU, Columbus, OH). Samples were collected by using the FACS Canto II flow cytometer (BD Biosciences, Franklin Lakes, NJ) and analyzed by using FlowJo (Ashland, OR) or Cytobank (Santa Clara, CA) software.
Donor-specific antibodies
Sera from recipient or control mice were diluted with phosphate-buffered saline and cocultured with thymocytes at 4°C. After washing, the thymocytes were stained with fluorescently labeled rat anti-mouse IgG Ab (eBioscience) and analyzed with the use of flow cytometry (25) .
2C adoptive transfers
B6 2C mice (23) were immunized with 20 9 10 6 BALB/c spleen cells.
Six days later, we harvested the spleen cells and isolated CD8 + T cells via negative-selection magnetic bead separation using an Automacs (Miltenyi Biotec, Bergisch Gladback, Germany). The enriched CD8 T cells were phenotyped (CD8 + and 1B2 + ) with the use of flow cytometry, and 5 9 10 6 CD8 + 2C + cells were injected into congenic WT or c3 À/À CD45.1 B6 hosts. The following day, the recipient mice underwent heterotopic heart transplantation with grafts exposed to 30 min or 8 h of CIS as described earlier; 48 h later, the mice were killed, and the allografts, spleens, and serum were collected for analysis.
Fate-mapping experiments
Rosa26-tomato-Foxp3GFP-ERT2Cre + fate-mapping mice (24) were immunized with 20 9 10 6 BALB/c spleen cells and concomitantly received MR1 (anti CD40-L; BioXcell, West Lebanon, NH) 1 mg i.p. on day À7 and a second dose of MR1 250 lg on day À4 to induce regulatory T cells (Tregs). The immunized mice were injected with tamoxifen 75 mg/kg dissolved in olive oil i.p. on days À7 to À2 to label Treg. Labeled CD4 + T cells were negatively selected (Automacs Miltenyi Biotec), and 8 9 10 6 cells were adoptively transferred into congenic B6 CD45.1 hosts on day À1 followed by heterotopic cardiac transplant on day 0 with WT BALB/c hearts along with CTLA4Ig as described earlier. Spleen cells from recipient mice were harvested and analyzed by flow cytometry on day 7.
Luminex cytokine assays
Cytokine analysis was performed on sera collected at 48-h posttransplantation by using the Luminex platform and Bio-Plex Pro Mouse Cytokine 23-plex Assay kit (Bio-Rad) per the manufacturer's instructions.
Statistics
Statistical analysis was performed by using Prism GraphPad software version 5 (La Jolla, CA). Survival statistics were calculated by MantelCox log rank test. All other experiments were analyzed by using two-tailed Student t-test with normal distribution, with adjustments for small samples sizes as required. A p-value <0.05 was considered significant.
Results
Building on our previous findings showing that 8-h CIS (but not 4-or 0.5-h CIS) induced peritransplantation inflammation associated with CTLA4Ig-resistant rejection (12), we tested the effects of 8-h CIS on survival of BALB/c hearts transplanted into B6 recipients [a different strain combination than previously described (12)] given a single dose of CTLA4Ig ( Figure 1A ). Donor hearts exposed to <30 min of CIS were rejected in untreated recipients with a median survival time ( À/À B6 recipients (n = 4-6/group). Recipients were treated with 250 lg CTLA4Ig i.p. on day 0 unless indicated otherwise. *p < 0.05 versus B/c?B6 8 h. Graft survival in all CTLA4Ig-treated groups was longer than in untreated controls. **p < 0.05 versus all conditions. (B) Representative hematoxylin and eosin-stained section of B/c heart subjected to 8-h cold ischemic storage (CIS) and transplanted into a CTLA4Ig-treated B6 recipient at cessation of palpable heartbeat, demonstrating diffuse mononuclear cell infiltration consistent with cellular rejection. Scale bar = 100 µm. (C) Representative serial sections stained for C4d, C3d, RB6 (neutrophils), Mac2 (macrophages), and CD3 (T cells) as indicated from WT B/c hearts subjected to 8-h CIS 48 h after transplantation into WT (upper panels) or c3 À/À (lower panels) B6 recipients. Scale bar in all panels = 200 µm. Red arrowheads delineate a blood vessel. Note that the pattern of C3d and C4d staining was similar to that of RB6 and Mac2. The data are representative of allografts from at least three different animals per group. but survived for >60 days in CTLA4Ig-treated hosts. In contrast, donor allografts exposed to 8-h CIS and transplanted into CTLA4Ig-treated hosts were rejected with a MST of 37 days (p < 0.05 vs. 30-min CIS). At rejection, histological analysis of the allografts exposed to 8-h CIS (in CTLA4Ig-treated recipients) showed diffuse mononuclear cell infiltrates consistent with acute cellular rejection (ACR; Figure 1B) . Sera collected at rejection showed low titers of DSAs that did not differ among groups (not shown). Together, the data demonstrate that prolonged donor CIS results in delayed, CTLA4Ig-resistant ACR.
We next tested whether and how complement impacts prolonged CIS-induced ACR in this model. We stained BALB/c hearts exposed to prolonged CIS and harvested at 48 h posttransplantation for C3d and C4d. These assays showed positive C3d and C4d staining within the graft parenchyma in regions that colocalized with infiltrating RB6 + neutrophils and Mac2 + macrophages and without perivascular or intravascular staining ( Figure 1C ). To determine whether recipient versus donor C3 mechanistically participates in prolonged CIS-induced ACR, we exposed WT or c3 À/À BALB/c hearts to 8 h of CIS and then transplanted them, respectively, into c3 À/À or WT B6 recipients and treated the recipients with a single dose of CTLA4Ig. Survival analyses ( Figure 1A) showed that recipient C3 deficiency reversed the effects of 8-h CIS, prolonging graft survival (MST >60 days) to that observed in WT recipients of WT allografts exposed to 30-min CIS. In contrast, c3 À/À donor allografts exposed to 8-h CIS were rejected (MST >41 days) with the same kinetics as WT allografts exposed to 8-h CIS. When we stained additional sets of allografts for complement activation products at 48 h posttransplantation, we did not detect C3d staining in WT grafts exposed to 8-h CIS transplanted into c3 À/À recipients (but did detect positive C4d staining, Figure 1C) , confirming that the deposited C3d was derived from the recipient. Together, the data implicate recipient C3 as an essential mediator of CTLA4Ig-resistant ACR in this system.
Increasing evidence indicates that early posttransplantation inflammation amplifies cellular infiltration into allografts and in turn augments allograft injury (12, 28) . At 48 h posttransplantation, we observed higher gene expression of interleukin (IL)-6, IL-1b, tumor necrosis factor (TNF)a, the chemokine CXCL1, and Toll-like receptor (TLR)-4 in allografts exposed to 8-h CIS and transplanted into WT recipients (Figure 2A , p < 0.05 for each). These changes were abrogated when donor allografts exposed to 8-h CIS were transplanted into c3 À/À recipients (Figure 2A) . We observed higher serum levels of IL-1b, TNFa, and IL-12 in WT recipients of donor grafts exposed to prolonged CIS versus 30 min CIS (p < 0.05). Absence of recipient C3 prevented these increases and, in fact, resulted in serum levels of TNFa, IL-1b, and IL-12 that were below those found in the WT B6 recipients of WT BALB/c allografts exposed to 30-min CIS (p < 0.05 for each).
To test the hypothesis that CI-induced, complementdependent allograft inflammation facilitates infiltration of activated T cells into the allografts, we transferred primed CD45.2, WT 2C (L d -reactive) cells into congenic CD45.1 WT or c3 À/À hosts ( Figure 3A, schematic) . We then transplanted WT BALB/c hearts exposed to 30 min or 8 h of CIS into the adoptive hosts and quantified graftinfiltrating cells via flow cytometry 48 h later (Figures 3C  and D) . These assays showed significantly more CD45.2 + CD8 + 2C T cells within allografts exposed to 8-h versus 30-min CIS (p < 0.05, Figure 3C ). The increase in graft infiltrating donor-reactive 2C T cells induced by 8-h donor CIS did not occur when the WT allografts were transplanted into c3 À/À recipients ( Figure 3C ). In control analyses, we observed similar numbers of 2C T cells in the spleens of all recipients (WT and c3 À/À regardless of donor status, Figure 3D ), supporting the conclusion that the increased numbers of 2C T cells detected in allografts exposed to 8-h CIS in WT hosts was a result of increased trafficking into the inflamed allograft. Quantification of host-derived CD45.1 + CD8 + T cells within the allografts showed a similar pattern: prolonged CIS induced a C3-dependent augmentation of host CD8 + T cell infiltration into the allografts ( Figure 3E ).
To determine the effects of 8-h donor CIS on induction of adaptive donor-reactive immune responses in WT and c3
À/À recipients, we performed additional sets of transplantations and killed the animals at 21 days posttransplantation for in vitro analyses ( Figure 4A ). These assays showed higher frequencies of donor-reactive, IFNc-producing spleen cells by ELISPOT in CTLA4Ig-treated WT recipients of WT grafts exposed to 8-h versus 30-min CIS. This increase was prevented when WT allografts exposed to 8-h CIS were transplanted into c3 À/À recipients ( Figure 4A ). Serum DSA titers were low in all animals and did not differ among groups ( Figure 4B ).
We and others reported that complement activation and inflammation can induce Foxp3 downregulation in Tregs, thereby limiting Treg-suppressive function (26, 29, 30) . We tested the effect of prolonged donor CIS on Treg stability through the use of Rosa26-tomato-Foxp3GFP-ERT2-Cre + fate-mapping mice (24) . In these animals, Foxp3
+ cells constitutively express green fluorescent protein (GFP), and tamoxifen treatment induces expression of dTomato Figure 5B), we observed equivalent percentages ( Figure 5C ) and absolute numbers ( Figure 5D ) of Foxp3-GFP neg dtomato + "ex-Tregs" in recipients of allografts exposed to 30 min or 8 h of CIS. Together with the effects of prolonged CIS on IFNc-producing effector T cells detailed here earlier (Figure 4A ), the data suggest that prolonged CIS augments expansion of donor-reactive T cells without altering the stability of Foxp3 expression in Tregs.
We next attempted to identify proximal initiators and amplifiers of complement activation in this system that could serve as potential therapeutic targets for preventing peritransplantation I/R injury and improving graft survival. To this end, we transplanted WT BALB/c hearts exposed to 8-h CIS into cfb Figure 6A ). In additional control experiments, we transplanted WT BALB/c hearts exposed to 8-h CIS into CTLA4Ig-treated WT B6 recipients and administered the C1-INH on days 7-8 posttransplantation, well beyond the time period of reperfusion injury. These allografts were rejected with similar kinetics to phosphate-buffered saline control-treated WT allografts exposed to 8-h CIS plus CTLA4Ig (MST = 42 days, p = NS) and significantly faster than those transplanted into recipients treated with CTLA4Ig plus C1-INH on days 0-1 (p < 0.05, Figure 6A ).
To assess the effects of peritransplantation C1-INH on T cell alloimmunity, we transplanted additional sets of WT hearts exposed to 8-h CIS into CTLA4Ig-treated WT recipients with or without C1-INH on days 0-1 and performed donor-reactive ELISPOT assays by using recipient spleen cells 21 days later (all grafts beating). These assays showed that peritransplantation treatment with C1-INH fully abrogated the prolonged CIS-induced increases in donor-reactive, IFNc-producing spleen cells ( Figure 6B ).
Discussion
Our results provide new insight into the mechanisms linking CIS-associated I/R injury to costimulatory blockade-resistant cardiac allograft rejection. Using a model of prolonged CIS, we demonstrate that CTLA4Ig-resistant rejection (Figure 1 ), early 48-h posttransplantation intragraft inflammation (Figure 2) , and primed CD8 + T cell infiltration into the allograft (Figure 3 ) are dependent on recipient C3. As the absence of recipient MBL, but not absence of recipient factor B, rescued prolonged survival despite 8-h CIS (Figure 6 ), the data support the conclusion that I/R-initiated, recipient, MBL-dependent, complement activation is pathogenically linked to delayed, CTLA4Ig-resistant rejection in this system.
We also newly demonstrate that peritransplantation administration of C1-INH rescued prolonged graft survival despite 8-h donor CIS (Figure 6 ). Together with the observations that delayed administration of C1-INH (days 7-8) was not effective (Figure 6 ) and the fact that C1-INH has a half-life of~22 h (35) , the data indicate that prolonged CIS leads to CTLA4Ig-resistent rejection through transient complement activation that occurs at the time of reperfusion. While our data cannot distinguish whether the effects of C1-INH are mediated via inhibition of MBL, classic pathway (C1qrs), and/or alternative pathways, the results from the mbl1 À/À mbl2 À/À mice imply that the protective effects of C1-INH are likely via inhibition of MBL activation.
A previous publication by others showed that myocardial I/R injury induces surface alterations on stressed myocardial cells, including exposure of carbohydrate moieties (e.g. L-fucose) that (a) bind collectin molecules and activate mannose-associated serine proteases and (b) upregulate cytokeratin-1 that can be recognized by MBL (17) . Oxidative stress also generates neoepitopes that can be ligated by naturally occurring IgM that in turn initiate MBL-dependent complement activation (16) (17) (18) 36) . Staining patterns of C3d/C4d within the allografts at 48 h (Figure 1 ) suggest complement activation occurs on cells within the parenchyma rather that within blood vessels. The observed colocalization of C3d/C4d with infiltrating neutrophils and macrophages (Figure 1 ) further suggests the possibility that graft damage by the cellular infiltrates permits MBL to escape the vasculature and bind ligands expressed on stressed cells. Deciphering the specific ligands/cells that serve as the target for complement activation and determining the role of natural IgM in this process will require additional experiments, including analyses performed at early postreperfusion time points (<24 h).
Building on previous studies showing that prolonged CIS augments endogenous memory CD8 + T cells infiltration into allografts (12) , our new data show that this process is recipient complement dependent ( Figure 4 ) and that CISdriven, complement activation at the time of reperfusion facilitates pathogenic donor-reactive T cell activation/ expansion 21 days later ( Figure 6 ). The mechanisms through which peritransplantation complement activation enhances delayed, pathogenic, donor-reactive T cell immunity remain to be fully deciphered. Our previous publications showed that immune cell-derived, alternative pathway-activated complement is crucial for alloreactive T cell immunity (25) (26) (27) 29, 37 ), but we contend that immune cell-derived complement is unlikely to account for the effects observed in the CIS system used in the current study. Survival of allografts exposed to 8-h CIS was not affected by the absence of recipient factor B, while C1-INH administration for only 48-h peritransplantation (but not on days 7-8) prevented both T cell expansion and graft rejection. We, therefore, speculate that the transient, reperfusion-induced complement activation initiates a proinflammatory milieu that has long-lasting effects on the development and function of pathogenic donor-reactive T cells capable of mediating rejection. While we and others have demonstrated that complement (29, 30, 38, 39) and proinflammatory cytokines, including IL-6 (40), inhibit Treg stability and function, our studies support that the dominant effect of complement in this system is to activate effector T cells (Figures 4 and 6 ) without altering Treg stability ( Figure 5 ). We acknowledge that we cannot exclude the possibility that Foxp3-expressing Tregs are functionally impaired in vivo.
Abatacept, the form of CTLA4Ig used in our studies, contains a series of directed mutations in the hinge region that abrogate complement activation (41) , making it unlikely that the improved allograft survival in C3-deficient mice is due to alterations in the pharmacokinetics of CTLA4Ig clearance. Moreover, our finding that transient, peritransplantation administration of C1-INH, which has a half-life of <24 h (35), overcomes CTLA4Ig-resistant rejection that occurs~40 days later supports a similar conclusion.
Our observation that peritransplantation C1-INH has remarkable, long-term protective effects in recipients given CTLA4Ig (Figure 6 ) has translational implications and supports the need for testing this combination of FDA-approved agents in nonhuman primates and in human kidney or heart transplant recipients. C1-INH is FDA approved for use in angioedema and has been studied in hundreds of subjects with minimal infectious or hematologic complications (e.g. thromboembolism), even with long-term use (42) (43) (44) . It is currently being tested to prevent antibody-mediated, complement-dependent rejection (ClinicalTrials.gov NCT02547220 and NCT0213 4314), and administering it peritransplantation is highly feasible. Specific MBL inhibitors being developed would be intriguing alternatives that would limit off-target effects on infectious immunity and avoid potential complications of blocking the C1q classic pathway, which has been shown to potentiate faster graft rejection under certain conditions (45) . Together, the data underscore the need to test the use of C1-INH as an adjunctive induction therapy in recipients of heart transplants (all of which are deceased donor transplants).
In summary, our data show that the inflammation and subsequent delayed T cell-mediated, costimulatory blockade-resistant cardiac allograft rejection induced by prolonged CIS is recipient MBL/complement dependent. Our data provide further evidence that complement is a critical mediator of not only early I/R injury in transplantation but also late adaptive immunity and offer a rationale to test the impact of perisurgical C1-INH therapy in human transplantation on immediate and late transplant outcomes, even in the absence of DSAs.
